Logo
x

Search

Subscribe Now

astellas

Astellas Reports the Health Canada’s Approval of Vyloy (Zolbetuximab) Plus Chemotherapy for Advanced G/GEJ Cancer

Astellas Reports the Health Canada’s Approval of Vyloy (Zolbetuximab) Plus Chemotherapy for Advanced G/GEJ Cancer

  • January 10, 2025
Astellas’ Vyloy (Zolbetuximab) Secures the NMPA’s Approval as a 1L Treatment of Advanced G/GEJ Adenocarcinoma

Astellas’ Vyloy (Zolbetuximab) Secures the NMPA’s Approval as a 1L Treatment of Advanced G/GEJ Adenocarcinoma

  • January 6, 2025
Astellas and Sangamo Therapeutics Partner for Administering Genomic Therapies Targeting Neurological Disorders

Astellas and Sangamo Therapeutics Partner for Administering Genomic Therapies Targeting Neurological Disorders

  • December 23, 2024
Astellas Reports MAA Withdrawn for Avacincaptad Pegol (ACP) in the EU

Astellas Reports MAA Withdrawn for Avacincaptad Pegol (ACP) in the EU

  • October 28, 2024
Astellas Reports the US FDA’s Approval of Vyloy (Zolbetuximab-clzb) to Treat Advanced G/GEJ Cancer

Astellas Reports the US FDA’s Approval of Vyloy (Zolbetuximab-clzb) to Treat Advanced G/GEJ Cancer

  • October 21, 2024
Astellas Join Forces with AviadoBio for AVB-101 Gene Therapy Targeting Frontotemporal Dementia and Other Indications

Astellas Join Forces with AviadoBio for AVB-101 Gene Therapy Targeting Frontotemporal Dementia and Other Indications

  • October 9, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.